Received 31 March 2013
aDepartment of Physics, Sri Subramanya College of Engineering & Technology, Palani 624 615, India,bDepartment of Physics, University College of Engineering, Nagercoil, Anna University, Tirunelveli Region, Nagercoil 629 004, India,cDepartment of Physics, Kalasalingam University, Krishnan Koil 626 190, India, and dDepartment of Organic Chemistry, Madurai Kamaraj University, Madurai 625 021, India
Correspondence e-mail: firstname.lastname@example.org
In the title compound, C30H28Cl3NO5S, the pyrrolidine ring adopts an envelope conformation (with the N atom as the flap) and the thiazine ring is in a distorted chair conformation. The molecular structure shows three intramolecular C-HO interactions leading to self-associated ring S(6) and two S(7) motifs. In the crystal, the molecules are linked by C-HO and C-HCl interactions. Two R22(10) and one R22(16) centrosymmetrically related ring motifs are observed in the unit cell and they are connected through C(6) and C(11) chain motifs extending along the b and c axes, respectively.
For the biological and pharmacological properties of thiazine, pyrrolidine and pyrrolothiazine compounds, see: Armenise et al. (1991, 1998); Hemming & Patel (2004); Koketsu et al. (2002); Kueh et al. (2003); Moriyama et al. (2004). For ring puckering analysis, see: Cremer & Pople (1975). For hydrogen-bonding interactions, see: Desiraju & Steiner (1999). For ring and chain motifs,see: Etter et al. (1990).
Data collection: SMART (Bruker, 2001); cell refinement: SAINT (Bruker, 2001); data reduction: SAINT; program(s) used to solve structure: SHELXTL/PC (Sheldrick, 2008); program(s) used to refine structure: SHELXTL/PC; molecular graphics: PLATON (Spek, 2009); software used to prepare material for publication: SHELXTL/PC.
Supplementary data and figures for this paper are available from the IUCr electronic archives (Reference: HG5304 ).
AC and SAB sincerely thank the Vice-Chancellor and Management of Kalasalingam University, Anand Nagar, Krishnan Koil, for their support and encouragement.
Armenise, D., Trapani, G., Arrivo, V. & Morlacchi, F. (1991). Il Farmaco, 46, 1023-1032.
Armenise, D., Trapani, G., Stasi, F. & Morlacchi, F. (1998). Arch. Pharm. 331, 54-58.
Bruker (2001). SAINT and SMART. Bruker AXS Inc., Madison, Wisconsin, USA.
Cremer, D. & Pople, J. A. (1975). J. Am. Chem. Soc. 97, 1354-1358.
Desiraju, G. R. & Steiner, T. (1999). In The Weak Hydrogen Bond in Structural Chemistry and Biology. New York: Oxford University Press Inc.
Etter, M. C., MacDonald, J. C. & Bernstein, J. (1990). Acta Cryst. B46, 256-262.
Hemming, K. & Patel, N. (2004). Tetrahedron Lett. 45, 7553-7556.
Koketsu, M., Tanaka, K., Takenaka, Y., Kwong, C. D. & Ishihara, H. (2002). Eur. J. Pharm. Sci. 15, 307-310.
Kueh, A. J., Marriott, P. J., Wynne, P. M. & Vine, J. H. (2003). J. Chromatogr. A, 1000, 109-124.
Moriyama, H., Tsukida, T., Inoue, Y., Yokota, K., Yoshino, K., Kondo, H., Miura, N. & Nishimura, S. (2004). J. Med. Chem. 47, 1930-1938.
Sheldrick, G. M. (2008). Acta Cryst. A64, 112-122.
Spek, A. L. (2009). Acta Cryst. D65, 148-155.